Risk-benefit effects of tocolytic therapy

Expert Opinion on Drug Safety

Volumn 3, Issue 6, 2004, Pages 639-654

  Pryde, Peter G ^a   Janeczek, Susan ^b   Mittendorf, Robert ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Efficacy; Magnesium sulphate; Safety; Tocolytic

Indexed keywords

ATOSIBAN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUPHENINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; GLUCOSE; INDOMETACIN; ISOXSUPRINE; MAGNESIUM SULFATE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; PHENYTOIN; POTASSIUM; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN G2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RITODRINE; SALBUTAMOL; SULINDAC; TERBUTALINE; THROMBOXANE; UNINDEXED DRUG; UTERUS SPASMOLYTIC AGENT;

ANURIA; APNEA; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; ECG ABNORMALITY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; HEADACHE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; ILEUS; IMMUNE DEFICIENCY; INFANT MORTALITY; JAUNDICE; LUNG DYSPLASIA; LUNG EDEMA; MATERNAL DISEASE; NAUSEA; NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NEUROPROTECTION; OLIGOHYDRAMNIOS; OLIGURIA; PREECLAMPSIA; PROCTITIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; STROKE; TACHYCARDIA; THORAX PAIN; TOCOLYSIS; TREMOR; UREMIA; VOMITING;

ADRENERGIC BETA-AGONISTS; ADULT; CALCIUM CHANNEL BLOCKERS; CEREBRAL HEMORRHAGE; CEREBRAL PALSY; CYCLOOXYGENASE INHIBITORS; FEMALE; FETAL DISEASES; HORMONE ANTAGONISTS; HUMANS; INFANT, NEWBORN; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; OBSTETRIC LABOR, PREMATURE; OXYTOCIN; PRE-ECLAMPSIA; PREGNANCY; RISK ASSESSMENT; TOCOLYSIS; TOCOLYTIC AGENTS;

EID: 8844260346     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.6.639     Document Type: Review

References (124)

1. REPORT OF THE CONCENSUS DEVELOPMENT CONFERENCE ON THE EFFECT OF CORTICOSTEROIDS FOR FETAL MATURATION ON PERINATAL OUTCOMES. National Institutes of Health. N.I.H. Publication. (1994) Number 95:3784.
2. PRYDE PG, BESINGER RE, GIANOPOULOS JG et al.: Adverse and beneficial effects of tocolytic therapy. Semin. Perinatol. (2001) 25:316-340.
3. MITTENDORF R, COVERT R, BOMAN J et al.: Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet (1997) 350:1517-1518.
4. BENNETT P, EDWARDS D: Use of magnesium sulphate in obstetrics. Lancet (1997) 350:1491.
5. NELSON KB, GRETHER JK: Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics (1995) 95:263-269.
6. MITTENDORF R, COVERT R, ELIN R et al.: Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstet. Gynecol. (2001) 98:75-78.
7. MITTENDORF R, DAMBROSIA J, PRYDE PG et al.: Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am. J. Obstet. Gynecol. (2002) 186:1111-1118.
8. CHESLEY LC: A survey of management and case mortality. In: Hypertensive disorders in pregnancy. Chesley LC (Ed.), Appleton-Century-Crofts, New York (1978).
9. MAHOMED K, GARNER P, DULEY L: Tocolytic magnesium sulphate and paediatric mortality. Lancet (1998) 351:293.
10. LUCAS MJ, LEVENO KJ, CUNNINGHAM FG: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N. Engl. J. Med. (1995) 333:201-205.
11. THE ECLAMPSIA TRIAL COLLABORATIVE GROUP: Which anticonvulsant for women with eclampsia: evidence from the Collaborative Eclampsia Trial. Lancet (1995) 345:1455-1463.
12. THE MAGPIE TRIAL COLLABORATIVE GROUP: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. Lancet (2002) 359:1877-1890.
13. BELFORT MA, ANTHONY J, SAADE GR et al.: Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N. Engl. J. Med. (2003) 348:304-311.
14. COTTON DB, STRASSNER HT, HILL LM et al.: Comparison of magnesium sulfate, terbutaline, and a placebo for inhibition of preterm labor. A randomized study. J. Reprod. Med. (1984) 29:92-97.
15. COX SM, SHERMAN ML, LEVENO KJ: Randomized investigation of magnesium sulfate for prevention of preterm birth. Am. J. Obstet. Gynecol. (1990) 163:767-772.
16. FOX MD, ALBERT JR, MCCAUL JF et al.: Neonatal morbidity between 34 and 37 week's gestation. J. Perinatol. (1993) 13 349-353.
17. HIGBY K, SUITE CR: A risk-benefit assessment of therapies for premature labour. Drug Saf. (1999) 1:35-56.
18. HIGBY K, XENAKIS EM, PAUERSTEIN CJ: Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am. J. Obstet. Gynecol. (1993) 168:1247-1259.
19. GYETVAI K, HANNAH ME, HODNETT ED et al.: Tocolytics for preterm labor: a systematic review. Obstet. Gynecol. (1999) 94 869-877.
20. KEIRSE MJ, GRANT A, KING JF: Preterm labor. In: A guide to effective care in pregnancy and childbirth. Enkin M, Keirse MJ, Renfrew MJ, Neilson JP (Eds), Oxford University Press, Oxford, UK (1995):161-173.
21. CROWTHER CA, HILLER JE, DOYLE LW: Magnesium sulphate for preventing preterm birth in threatened preterm labor. Cochrane Database of Systematic Reviews (2003) March.
22. MITTENDORF R, PRYDE P, KHOSHNOOD B et al.: If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet. Gynecol. (1998) 92:308-311.
23. MITTENDORF R, DAMBROSIA J, DAMMANN O et al.: Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. J. Pediatr. (2002) 140 540-546.
24. GAWAZ M, OTT I, REININGER AJ et al.: Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb. Haemost. (1994) 72:912-918.
25. ASSALEY J, BARON JM, CIBILS LA: Effects of magnesium sulfate infusion upon clotting parameters in patients with pre-eclampsia. J. Perinat. Med. (1998) 26:115-119.
26. 4. Am. J. Obstet. Gynecol. (2001) 185:S151.
27. LEE K-S, MITTENDORF R, BESINGER RE et al.: Mechanisms of mortality in the Magnesium and Neurologic Endpoints Trial (MagNET Trial): Papile grade III neonatal intraventricular hemorrhage. Pediatr. Res. (2002) 51:411A.
28. SCHENDEL DE, BERG CJ, YEARGIN-ALLSOPP M et al.: Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA (1996) 276:1805-1810.
29. CROWTHER CA, HILLER JE, DOYLE LW et al.: Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA (2003) 290:2669-2676.
30. BISHOP EH, WOUTERSZ TB: Isoxsuprine, a myometrial relaxant. Obstet. Gynecol. (1961) 17:442-446.
31. HENDRICKS CH, CIBILS LA, POSE SV et al.: The pharmacologic control of excessive uterine activity with isoxsuprine. Am. J. Obstet. Gynecol. (1961) 82:1064-1078.
32. FDA: Ritodrine approved for premature labor: FDA. Drug Bull. (1980) 10:22-23.
33. CARSTEN ME, MILLER JD: A new look at uterine muscle contraction. Am. J. Obstet. Gynecol. (1987) 157:1303-1315.
34. SCHEID CR, HONEYMAN TW, FAY FS: Mechanism of beta-adrenergic relaxation of smooth muscle. Nature (1979) 277:32-36.
35. BERG G, ANDERSSON RG, RYDEN G: Beta-adrenergic receptors in human myometrium, during pregnancy: changes in the number of receptors after beta-mimetic treatment. Am. J. Obstet. Gynecol. (1985) 151 392-396.
36. CARITIS SN, CHIAO JP, MOORE JJ et al.: Myometrial desensitization after ritodrine infusion. Am. J. Physiol. (1987) 253:E410-E417.
37. KING JF, GRANT A, KEIRSE MJ et al.: Beta-mimetics in preterm labour: an overview of the randomized controlled trials. BJOG (1988) 95:211-222.
38. CANADIAN PRETERM LABOR INVESTIGATION GROUP: Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N. Engl. J. Med. (1992) 327:308-312.
39. MACONES GA, BERLIN M, BERLIN JA: Efficacy of oral beta-agonist maintenance therapy in preterm labor: a meta-analysis. Obstet. Gynecol. (1995) 85:313-317.
40. HANKINS GD: Complications of beta-sympathomimetic tocolytic agents. In: Critical Care Obstetrics. Clark SL, Cotton DB, Hankins GD, Phelan JP (Eds), Blackwell Scientific Publications, Boston, MA, USA (1991):223-250.
41. GROSPIETSCH G, FENSKE M, GIRNDT J et al.: The renin-angiotensin-aldosterone system, antidiuretic hormone levels and water balance under tocolytic therapy with fenoterol and verapamil. Int. J. Gynaecol. Obstet. (1980) 17:590-595.
42. CANO A, TOVAR I, PARRILLA JJ et al.: Metabolic disturbances during intravenous use of ritodrine: increased insulin levels and hypokalemia. Obstet. Gynecol. (1985) 65:356-360.
43. ROSENE KA, FEATHERSTONE HJ, BENEDETTI TJ: Cerebral ischemia associated with parenteral terbutaline use in pregnant migraine patients. Am. J. Obstet. Gynecol. (1982) 143:405-407.
44. LEVENO KJ, CUNNINGHAM FG: Beta-adrenergic agonists for preterm labor. N. Engl. J. Med. (1992) 327:349-351.
45. MICHALAK D, KLEIN V, MARQUETTE GP: Myocardial ischemia: a complication of ritodrine tocolysis. Am. J. Obstet. Gynecol. (1983) 146:861-862.
46. FINLEY J, KATZ M, ROJAS-PEREZ M et al.: Cardiovascular consequence of beta-agonist tocolysis: an echocardiographic study. Obstet. Gynecol. (1984) 64:787-791.
47. NAIR GV, GHOSH AK, LEWIS BV: Bowel distention during treatment of premature labor with beta-receptor agonists. Lancet (1976) 1:907.
48. SHENKER L: Effect of isoxsuprine on fetal heart rate and fetal electrocardiogram. Obstet. Gynecol. (1965) 26:104-109.
49. KATZ VL, SEEDS JW: Fetal and neonatal cardiovascular complications from beta-sympathomimetic therapy for tocolysis. Am. J. Obstet. Gynecol. (1989) 161:1-4.
50. VAN ASSCHE FA, AERTS L: The effect of beta-sympathomimetics on the fetal endocrine pancreas. Eur. J. Obstet. Gynecol. Reprod. Biol. (1983) 15:395-408.
51. LEAKE RD, HOBEL CJ, OKADA DM et al.: Neonatal metabolic effects of oral ritodrine hydrochloride administration. Pediatr Pharmacol (1983) 3:101-106.
52. BRAZY JE, PUPKIN MJ: Effects of maternal isoxsuprine administration on preterm infants. J. Pediatr. (1979) 94 444-448.
53. GROOME LJ, GOLDENBERG RL, CLIVER SP et al.: Neonatal periventricular-intraventricular hemorrhage after maternal beta-sympathomimetic tocolysis. The March of Dimes Multicenter Study Group. Am. J. Obstet. Gynecol. (1992) 167:873-879.
54. PRANIKOFF J, HELMCHEN R, EVERTSON L: Tocolytic therapy and intraventricular hemorrhage in the neonate. Am. J. Obstet. Gynecol. (1991) 164:387.
55. OZCAN T. TURAN C, EKICI E et al.: Ritodrine tocolysis and neonatal intraventricular-periventricular hemorrhage. Gynecol. Obstet. Invest. (1995) 39:60-62.
56. FREYSZ H, WILLARD D, LEHR A et al.: A long term evaluation of infants who received a beta-mimetic drug while in utero. J. Perinat. Med. (1977) 5:94-99.
57. KARLSSON K, KRANTZ M, HAMBERGER L: Comparison of various betamimetics on preterm labor, survival and development of the child. J. Perinat. Med. (1980) 8:19-26.
58. SVENNINGSEN NW: Follow-up studies on preterm infants after maternal beta-receptor agonist treatment. Acta Obstet. Gynecol. Scand. Suppl. (1982) 108:67-70.
59. ZUCKERMAN H, REISS U, RUBINSTEIN I: Inhibition of human premature labor by indomethacin. Obstet. Gynecol. (1974) 44 787-792.
60. MACONES GA, MARDER SJ, CLOTHIER B et al.: The controversy surrounding indomethacin for tocolysis. Am. J. Obstet. Gynecol. (2001) 184:262-272.
61. HANNAH ME: Search for best tocolytic for preterm labor. Lancet (2000) 356:699-700.
62. MACONES GA, ROBINSON CA: Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am. J. Obstet. Gynecol. (1997) 177:819-824.
63. GORDON MC, SAMUELS P: Indomethacin. Clin. Obstet. Gynecol. (1995) 38:697-705.
64. ZUCKERMAN H, SHALEV E, GILAD G et al.: Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J. Perinat. Med. (1984) 12:25-29.
65. PANTER KR, HANNAH ME, AMANKWAH KS et al.: The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. BJOG (1999) 106:467-473.
66. MORALES WJ, MADHAV H: Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am. J. Obstet. Gynecol. (1993) 169:97-102.
67. MORALES WJ, SMITH SG, ANGEL JL et al.: Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstet. Gynecol. (1989) 74 567-572.
68. BESINGER RE, NIEBYL JR, KEYES WG et al.: Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am. J. Obstet. Gynecol. (1991) 164 981-988.
69. GYETVAI K, HANNAH MR, HODNETT ED et al.: Tocolytics for preterm labor: a systematic review. Obstet. Gynecol. (1999) 94 869-877.
70. KEIRSE MH: Indomethacin tocolysis in preterm labour. In: Pregnancy and Child-birth module of the Cochrane Database of Systematic Reviews. Enkin M, Keirse M, Renfrew M, Neilson J (Eds), BMJ Publishing Group, London (1995).
71. REPKE JT, NIEBYL JR: Role of prostaglandin synthetase inhibitors in the treatment of preterm labor. Semin. Reprod. Endocrinol. (1985) 3:259-272.
72. STEIGER RM, BOYD EL, POWERS DR et al.: Acute maternal renal insufficiency in premature labor treated with indomethacin. Am. J. Perinatol. (1993) 10:381-383.
73. GALLER M, FOLKERT VW, SCLONDORFF D: Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA (1981) 246:154-155.
74. LUNT CC, SATIN AJ, BARTH WH Jr et al.: The effect of indomethacin tocolysis on maternal coagulation status. Obstet. Gynecol. (1994) 84:820-822.
75. DURANDY A, BRAMI C, GRISCELLI C: The effects of indomethacin administration during pregnancy on women's and newborns' T-suppressor lymphocyte activity and on HLA Class II expression by newborns' leukocytes. Am. J. Reprod. Immunol. (1985) 8:94-100.
76. CANTOR B, TYLER T, NELSON RM et al.: Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors. J. Reprod. Med. (1980) 24:240-223.
77. MARI G, MOISE KJ Jr, DETER RL et al.: Doppler assessment of the renal blood flow velocity waveform during indomethacin therapy for preterm labor and polyhydramnios. Obstet. Gynecol. (1990) 75:199-201.
78. WIGGINS DA, ELLIOT JP: Oligohydramnios in each sac of a triplet gestation caused by Motrin-fulfilling Kock's postulates. Am. J. Obstet. Gynecol. (1990) 162:460-461.
79. GLOOR JM, MUCHANT DG, NORLING LL: Prenatal maternal indomethacin use resulting in prolonged neonatal renal insufficiency. J. Perinatol. (1993) 13:425-427.
80. NIEBYL JR, WITTER FR: Neonatal outcome after indomethacin treatment for preterm labor. Am. J. Obstet. Gynecol. (1986) 155 747-749.
81. MOISE KJ Jr: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am. J. Obstet. Gynecol. (1993) 168 1350-1353.
82. MOISE KJ Jr, HUHTA JC, SHARIF DS et al.: Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N. Engl. J. Med. (1988) 319:327-331.
83. HUHTA JC, MOISE KJ, FISHER DJ et al.: Detection and quantitation of constriction of the fetal ductus arteriosus by Doppler echocardiography. Circulation (1987) 75:406-412.
84. SAENGER JS, MAYER DC, D'ANGELO LJ et al.: Ductus-dependent fetal cardiac defects contraindicate indomethacin tocolysis. J. Perinatol. (1992) 12:41-47.
85. MANCHESTER D, MAROLIS HS, SHELDON RE: Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am. J. Obstet. Gynecol. (1976) 126:467-469.
86. LEVIN DL, FIXLER DE, MORRISS FC et al.: Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J. Pediatr. (1978) 92 478-483.
87. NORTON ME, MERRILL J, COOPER BA et al.: Neonatal complications after the administration of indomethacin for preterm labor. N. Engl. J. Med. (1993) 329:1602-1607.
88. KATZ Z, LANCET M, YEMINI M et al.: Treatment of premature labor contractions with combined ritodrine and indomethacin. Int. J. Gynaecol. Obstet. (1983) 21:337-342.
89. MARPEAU L, BOUILLIE J, BARRAT J et al.: Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn. Ther. (1994) 9:110-115.
90. NORTON M, MERILL J, COOPER B et al.: Neonatal complications after the administration of indomethacin for preterm labor. N. Engl. J. Med. (1993) 329:1602-1607.
91. ERONEN M, PESONEN E, KURKI T et al.: Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterrm labor. J. Pediatr. (1994) 124 782-788.
92. GARDNER MO, OWEN J, SKELLY S et al.: Preterm delivery and indomethacin: a risk factor for neonatal complications? J. Reprod. Med. (1996) 41:903-906.
93. VERMILLION ST, NEWMAN RB: Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am. J. Obstet, Gynecol. (1999) 181:1083-1086.
94. NUKI G: Non-steroidal analgesic and anti-inflammatory agents. Br. Med. J. (1983) 287:39-43.
95. BUNNING RD, BARTH WF: Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA (1982) 248 2864-2867.
96. KRAMER WB, SAADE G, OU CN et al.: Placental transfer of sulindac and its active sulfide metabolite in humans. Am. J. Obstet. Gynecol. (1995) 172:886-890.
97. RASANEN J, JOUPPILA P: Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am. J. Obstet. Gynecol. (1995) 173:20-25.
98. KRAMER WB, SAADE GR, BELFORT M et al.: A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor. Am. J. Obster. Gynecol. (1999) 180:396-401.
99. CLYMAN RI, HARDY P, WALEH N et al.: Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am. J. Physiol. (1999) 276:R913-R921.
100. LOCATELLI A, VERGANI P, BELLINI P et al.: Can a cylooxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG (2001) 108:325-326.
101. MACONES GA, ROBINSON CA: Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am. J. Obstet. Gynecol. (1997) 177:819-824.
102. ULMSTEN W, ANDERSSON KE, WINGERUP L: Treatment of premature labor with the calcium antagonist nifedipine. Arch. Gynecol. (1980) 229:1-5.
103. BRAUNWALD E: Mechanism of action of calcium-channel-blocking agents. N. Engl. J. Med. (1982) 307:1618-1627.
104. READ MD, WELLBY DE: The use of calcium antagonist (nifedipine) to suppress preterm labour. BJOG (1986) 93 933-937.
105. PAPATSONIS DN, VAN GEIJN HP, ADER HJ et al.: Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet. Gynecol. (1997) 90:230-234.
106. PAPATSONIS DN, KOK JH, VAN GEIJN HP et al.: Neonatal effects of nifedipine and ritodrine for preterm labor. Obstet. Gynecol. (2000) 95:477-481.
107. KING JF, FLENADY VJ, PAPATSONIS DN, DEKKER GA, CARBONNE B: Calcium channel blockers for inhibiting preterm labor. Cochrane Database Syst. Rev. (2003) 1:CD002255.
108. CAUVIN C, LOUTZENHISER R, VAN BREEMEN C: Mechanisms of calcium antagonist-induced vasodilation. Annu. Rev. Pharmacol. Toxicol. (1983) 23:373-396.
109. ANONYMOUS: Hypotension and coronary events on nifedipine: reassessing nifedipine safety. Prescrire Int. (1998) 7:90-91.
110. FISCHBERG GM, LOZANO E, RAJAMANI K et al.: Stroke precipitated by moderate blood pressure reduction. J. Emerg. Med. (2000) 19:339-346.
111. AHR HJ, BOMHARD E, MAGER E et al.: Calcium channel blockers and cancer: is there preclinical evidence for an association? Cardiol. (1997) 88:68-72.
112. DAVIS WB, WELLS SR, KULLER JA et al.: Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet. Gynecol. Surv. (1997) 52 198-201.
113. OEI SG, OEI SK, BROLMANN HA: Myocardial infarction during nifedipine therapy for preterm labor. N. Engl. J. Med. (1999) 340:154.
114. SNYDER SW, CARDWELL MS: Neuromuscular blockade with magnesium sulfate and nifedipine. Am. J. Obstet. Gynecol. (1989) 161 35-36.
115. IAMS J: Preterm birth. In: Obstetrics: Normal and Problem Pregnancies. Gabbe SG, Niebyl JR, Simpson JL (Eds), Churchill Livingstone, New York (1996):743-820.
116. PARISI VM, SALINAS J, STOCKMAR EJ: Fetal vascular response to maternal nicardipine administration in the hypertensive ewe. Am. J. Obstet. Gynecol. (1989) 161:1035-1039.
117. MARI G, KIRSHON B, MOISE KH Jr et al.: Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am. J. Obstet. Gynecol. (1989) 161 1514-1518.
118. MELIN P, TROJNAR J, JOHANSSON B et al.: Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. (1986) 111:125-131.
119. AKERLUND M, STROMBERG P, HAUKSSON A et al.: Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. BJOG (1987) 94:1040-1044.
120. MOUTQUIN JM, SHERMAN D, COHEN H et al.: Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am. J. Obstet. Gynecol. (2000) 182:1191-1199.
121. THE WORLDWIDE ATOSIBAN VERSUS BETA-AGONISTS STUDY GROUP: Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG (2001) 108:133-142.
122. GOODWIN TM, ZOGRABYAN A: Oxytocin receptor antagonists. Update. Clin. Perinatol. (1998) 25:859-871.
123. BOSSMAR T, AKERLUND M, FANTONI G et al.: Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effects of oxytocin receptor antagonist atosiban. Am. J. Obstet. Gynecol. (1994) 171:1634-1642.
124. ROMERO R, SIBAI BM, SANCHEZ-RAMOS L et al.: An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. (2000) 182:1173-1183.